Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

NCT02819804 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Due to funding and accrual issues

Conditions

B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1
Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent Childhood Acute Lymphoblastic Leukemia
Refractory Adult Acute Lymphoblastic Leukemia
Refractory Childhood Acute Lymphoblastic Leukemia

Interventions

DRUG: Dasatinib
OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Nivolumab
OTHER: Pharmacological Study

Sponsor

Northwestern University

Collaborators

[object Object]